Short answer: In the one head-to-head trial we have, tirzepatide (Zepbound) came out ahead of semaglutide (Wegovy) — about 20% average body weight loss versus about 14% at the highest approved doses over 72 weeks. But “better on average” and “better for you” aren’t the same thing. Your health history, how you handle side effects, what your insurance covers, and how your body actually responds all matter more than a trial average.
If you’ve been researching GLP-1 medications for weight loss, you’ve run into both names by now — along with a lot of conflicting takes and a fair amount of marketing dressed up as information. Here’s the straightforward version: what the research shows, what it costs, and how we decide which one to start you on.
Semaglutide vs. Tirzepatide: What’s Actually Different
The core difference comes down to how many hormone receptors each medication activates — and that matters more than it sounds like it would.
Semaglutide is a GLP-1 receptor agonist. It mimics one hormone — glucagon-like peptide-1 — which signals fullness, slows how quickly your stomach empties, and helps regulate blood sugar. The FDA approved it for chronic weight management under the brand name Wegovy in June 2021.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It targets two hormones: GLP-1, same as semaglutide, plus GIP — glucose-dependent insulinotropic polypeptide. GIP works alongside GLP-1 to boost insulin release, support fat metabolism, and may add to that feeling of fullness. The FDA approved tirzepatide (Zepbound) for weight loss in November 2023, making it the first obesity treatment of its kind to work on both receptors.
That dual mechanism is the main reason tirzepatide posts stronger numbers head-to-head. It isn’t a more powerful version of the same drug — it’s a meaningfully different approach.
What the Head-to-Head Trial Actually Found
For years, all we had were indirect comparisons — separate trials, different patient groups, different designs. SURMOUNT-5 changed that. It’s the first direct randomized trial comparing tirzepatide and semaglutide in adults with obesity, published in the New England Journal of Medicine.
| Metric | Semaglutide (Wegovy) — STEP Trials | Tirzepatide (Zepbound) — SURMOUNT-5 |
|---|---|---|
| Average weight loss | ~15% at 68 weeks (STEP 1) | ~20.2% at 72 weeks |
| Head-to-head comparison arm | −13.7% body weight at 72 weeks | −20.2% body weight at 72 weeks |
| % achieving ≥25% weight loss | ~16.1% | ~31.6% |
| Max approved weekly dose | 2.4 mg subcutaneous injection | 15 mg subcutaneous injection |
| FDA approval for weight loss | June 2021 | November 2023 |
| Dosing schedule | Once weekly injection | Once weekly injection |
In SURMOUNT-5, 751 patients were randomly assigned to the maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg), injected once a week. At 72 weeks, the average change in body weight was −20.2% for tirzepatide versus −13.7% for semaglutide. And 31.6% of the tirzepatide group lost at least 25% of their body weight, compared with 16.1% on semaglutide.
Real-world numbers line up with the trial. In a retrospective study of nearly 2,400 patients, tirzepatide produced greater average weight loss at six months (−11.15% vs. −8.83%) and more patients hit their weight-loss targets.
One caveat worth saying out loud: these are averages. Plenty of people respond beautifully to semaglutide and have no reason to switch. The data tells us what tends to happen — not what will happen for you.
Side Effects: More Alike Than Different
Both medications share a similar stomach-related side-effect profile, because both act on GLP-1 receptors. If you’ve heard that one is “gentler” than the other, the reality is a little more nuanced.
What They Have in Common
Both can cause gastrointestinal issues — nausea, vomiting, diarrhea. These are usually worst during dose increases and settle down as your body adjusts. The standard approach for both is the same: start low, go up slowly.
- Nausea — the most common one, especially while you’re titrating
- Diarrhea or constipation
- Vomiting — more likely at higher doses
- Decreased appetite — the intended effect, but it can feel strange at first
If nausea is the part you’re worried about, we wrote a whole post on how to relieve nausea on Tirzepatide — five things that actually help.
Where They May Differ
Tirzepatide’s GIP component may offer a bit of a tolerance advantage. Research suggests GIP receptor activity has an anti-nausea effect, which could take the edge off some of the nausea and vomiting that come with GLP-1 medications. It doesn’t make tirzepatide side-effect-free, though — it still activates GLP-1 receptors, so GI symptoms can absolutely still show up, especially at higher doses.
In SURMOUNT-5, more patients stopped treatment because of GI side effects on semaglutide (5.6%) than on tirzepatide (2.7%). That’s a real clinical difference — just not a guarantee.
Either way, careful titration is the whole game. We manage that closely with you: starting slow is how we keep you comfortable and keep you on track.
Cost and Coverage: The Practical Part
This is where the comparison gets real, and sometimes frustrating. Both medications carry serious list prices, and insurance coverage is inconsistent for both.
Brand-Name List Prices
Wegovy (semaglutide) runs roughly $1,350–$1,640 a month without insurance; Zepbound (tirzepatide) is around $1,271 a month. What you actually pay shifts with dose, pharmacy, and location — treat these as reference points, not quotes.
Manufacturer Savings Programs
Without insurance, Zepbound self-pay pricing through Eli Lilly starts around $299 for a 2.5 mg vial or KwikPen, $399 a month at 5 mg, and $449 a month for higher doses. With commercial insurance and a Zepbound savings card, that can drop to $25 for a one-month or three-month prescription. Novo Nordisk runs comparable programs for Wegovy — eligibility and terms vary.
Insurance Coverage
Coverage depends on your plan and on why the medication is being prescribed. Both are FDA-approved for weight loss, but they’re more likely to be covered for their other approved uses — obstructive sleep apnea for Zepbound, heart disease for Wegovy. Even then the rules aren’t uniform, and benefits vary by employer plan and state.
Most commercial plans cover GLP-1s only with prior authorization, typically after a documented BMI of 35 or higher and six or more months of lifestyle intervention. That’s a real barrier for a lot of people — and it’s something we help you work through at your consultation.
A medication you can’t afford to stay on isn’t a solution. We factor cost and coverage into every recommendation we make.
How We Choose Between Them at Sakura Skin
We don’t default to one medication. Everyone who comes into our Fenton or Flint location gets a personal review, because the better drug on paper isn’t always the right fit in practice. Here’s what we look at:
- Your medical history. Thyroid conditions, kidney function, and any personal or family history of pancreatitis affect eligibility and risk for both medications. That’s a real conversation, not a checkbox.
- What you’ve already tried. If you plateaued on semaglutide, couldn’t tolerate the side effects, or just didn’t respond the way you hoped, tirzepatide’s different mechanism may be worth a look.
- Your goals. If you’re aiming for 20% or more, tirzepatide’s trial data is hard to ignore. If your goals are more modest, semaglutide may do the job beautifully.
- Cost and coverage. We look at what’s actually affordable and sustainable long-term, including savings card eligibility and whether brand-name makes sense for your situation.
- Your tolerance for side effects. If you’re GI-sensitive, we titrate more slowly — whichever medication we land on. Low and slow is almost always the right call.
And if menopause is part of your picture, that changes the conversation too — we get into it in Can GLP-1 Shots Help With Menopause Weight Gain?
Does This Sound Like You?
You’re probably here because one of these is true:
- You’re comparing GLP-1s and drowning in conflicting information online
- You’ve tried one medication and wonder whether the other would work better
- You’re worried about side effects and want an honest comparison, not a sales pitch
- You want to understand the real cost before committing to anything
- An ad told you you’re “a good candidate” and you’d like an actual clinical opinion
All fair reasons. And none of them can be fully answered by a blog post — which is exactly what a consultation is for.
Frequently Asked Questions
Is tirzepatide stronger than semaglutide for weight loss?
In the head-to-head SURMOUNT-5 trial, tirzepatide averaged 20.2% body weight reduction versus 13.7% for semaglutide over 72 weeks — so by trial averages, yes. Individual responses vary, though, and plenty of people do very well on semaglutide without needing to switch.
Do tirzepatide and semaglutide have the same side effects?
They share a similar GI profile — nausea, diarrhea, constipation, and vomiting — because both activate GLP-1 receptors. Tirzepatide’s added GIP activity may reduce nausea for some people; in SURMOUNT-5, more patients stopped semaglutide over GI side effects (5.6%) than tirzepatide (2.7%). Side effects are usually worst during dose increases and improve over time.
Which is cheaper — Wegovy or Zepbound?
At list price, both are well over $1,000 a month without insurance or savings programs. Zepbound’s self-pay vial program through LillyDirect starts around $299 a month at the lowest dose, and Wegovy has comparable savings programs. What you actually pay depends on your insurance, your dose, and whether you qualify for a manufacturer savings card.
Can I switch from semaglutide to tirzepatide if I’ve plateaued?
Yes — switching is a normal thing to consider after a plateau or intolerable side effects. Because tirzepatide works on two receptors instead of one, some people who didn’t respond fully to semaglutide see additional benefit. A provider should guide the transition, including the right dose and timing.
Are tirzepatide and semaglutide FDA-approved for weight loss?
Yes. Semaglutide (Wegovy) was FDA-approved for chronic weight management in June 2021, and tirzepatide (Zepbound) for weight loss in November 2023. Both are approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related health condition, used alongside a reduced-calorie diet and more physical activity.
Not Sure Which GLP-1 Is Right for You?
This isn’t a decision to make from a blog post alone, and you shouldn’t have to. Schedule a consultation at our Fenton or Flint location and we’ll go through your medical history, your goals, and your budget, then recommend a starting point that makes sense for your body. No pressure — just a real conversation with a provider who knows the difference between what the trials say and what works for the person in front of them.
Ready to talk it through? Call 810-394-2187 or Text 810-512-2496 — or book online at calendly.com/sakuraskin. We’re in Fenton and Flint, MI.